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Research
AbstrACt
Objectives To compare the cost-effectiveness (CE) of 
the National Institute for Health and Care Excellence 
(NICE) 2015 and the WHO 2013 diagnostic thresholds for 
gestational diabetes mellitus (GDM).
setting The analysis was from the perspective of the 
National Health Service in England and Wales.
Participants 6221 patients from four of the 
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) 
study centres (two UK, two Australian), 6308 patients 
from the Atlantic Diabetes in Pregnancy study and 12 755 
patients from UK clinical practice.
Primary and secondary outcome measures 
planned The incremental cost per quality-adjusted 
life year (QALY), net monetary benefit (NMB) and the 
probability of being cost-effective at CE thresholds of 
£20 000 and £30 000 per QALY.
results In a population of pregnant women from 
the four HAPO study centres and using NICE-defined 
risk factors for GDM, diagnosing GDM using NICE 
2015 criteria had an NMB of £239 902 (relative to 
no treatment) at a CE threshold of £30 000 per QALY 
compared with WHO 2013 criteria, which had an NMB 
of £186 675. NICE 2015 criteria had a 51.5% probability 
of being cost-effective compared with the WHO 2013 
diagnostic criteria, which had a 27.6% probability 
of being cost-effective (no treatment had a 21.0% 
probability of being cost-effective). For women without 
NICE risk factors in this population, the NMBs for 
NICE 2015 and WHO 2013 criteria were both negative 
relative to no treatment and no treatment had a 78.1% 
probability of being cost-effective.
Conclusion The NICE 2015 diagnostic criteria for 
GDM can be considered cost-effective relative to the 
WHO 2013 alternative at a CE threshold of £30 000 per 
QALY. Universal screening for GDM was not found to be 
cost-effective relative to screening based on NICE risk 
factors.
IntrOduCtIOn
The diagnostic glycaemic thresholds for 
gestational diabetes mellitus (GDM) remain 
the subject of considerable debate. The 
original definition was based on maternal 
risk for developing postpartum diabetes, 
but subsequent thresholds have concen-
trated on complications during pregnancy 
and the health of the offspring. The publi-
cation of the Hyperglycaemia and Adverse 
Pregnancy Outcomes (HAPO) study1 
demonstrated a linear association between 
increasing levels of maternal hypergly-
caemia and adverse perinatal outcomes 
with no obvious threshold, an association 
that has also been observed in subsequent 
analyses.2 The discussion around the diag-
nostic criteria that should define GDM has 
intensified. New diagnostic thresholds were 
proposed by the International Association 
of Diabetes in Pregnancy Study Group3 
based on the HAPO study levels of plasma 
glucose when fasting and at 1 and 2 hours 
after an oral 75 g glucose load that were 
strengths and limitations of this study
 ► This economic evaluation addresses an important 
clinical and policy issue. The existing economic 
evidence is limited and WHO has stated that studies 
of this type are needed to inform a future update of 
their guideline.
 ► Our paper has used patient-level data from the 
influential Hyperglycaemia and Adverse Pregnancy 
Outcomes study for an economic analysis that 
has not been previously been published in a peer-
reviewed journal.
 ► This analysis provides clear evidence that universal 
screening is not cost-effective in the UK.
 ► This analysis suggests that the National Institute for 
Health and Care Excellence diagnostic criteria for 
gestational diabetes mellitus are more cost-effective 
than the WHO criteria in the UK context.
 ► Model conclusions are sensitive to uncertainties 
with respect to valuation of health outcomes and 
the possible long-term metabolic consequences 
for offspring for which the evidence is debated and 
which are hard to quantify.
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associated with covariate adjusted OR of 1.75 relative to 
the mean glucose value in the whole HAPO cohort on 
three offspring outcomes: exceeding the 90th centile for 
birth weight, for cord serum C-peptide concentration 
and for percent fetal body fat. These diagnostic criteria 
have been subsequently adopted by WHO.4 However, 
they remain controversial and have not been supported 
by bodies such as the National Institutes for Health and 
the American College of Obstetricians.5 Furthermore, 
WHO has acknowledged that they will have to be revis-
ited in the near future in light of new studies reporting 
their cost-effectiveness.4
In 2015 National Institute for Health and Care Excel-
lence (NICE) published an updated guidance on diabetes 
in pregnancy,6 which included recommendations on 
diagnostic thresholds for GDM that differ from those 
adopted by WHO. These NICE thresholds were informed 
by an economic evaluation of the type that WHO consid-
ered important to inform future recommendations but 
have attracted criticism in the UK7 and elsewhere. Data 
from a published Spanish study8 have been widely cited7 9 
in support of the cost-effectiveness of the WHO criteria, 
although a UK analysis has more recently suggested that 
it is not cost-effective to identify gestational diabetes for 
treatment.10
In this paper, we compared the cost-effectiveness of 
NICE 2015 and WHO 2013 diagnostic thresholds for 
GDM, as these are new thresholds proposed by national 
and international bodies. The analysis was undertaken 
using a revised version of the health economic model 
developed for the NICE guideline and was based on 
data from the UK and Australian HAPO study centres.
MethOds
Model description
A decision analytic framework was used to evaluate the 
cost-effectiveness of two recently proposed diagnostic 
thresholds for GDM, together with a no diagnosis/no 
treatment option (see table 1). A schematic of the model 
is shown in figure 1. Cost-effectiveness was evaluated using 
both deterministic and probabilistic sensitivity analyses.
Population
The model population comprised women of gestational 
age 24–28 weeks without pre-existing diabetes. The 
analysis used individual patient data from three data-
sets, which, although not restricted to the UK, provide 
a representative cross-section of the demographic and 
patient characteristics that would be found in the UK 
(online supplementary table x1 in the supplementary 
report provides a breakdown of ethnic groups in each 
of our datasets). The analyses were run separately for 
each dataset and, where possible, for subgroups with and 
without risk factors (RFs) for GDM within a dataset.
1. HAPO: a dataset from the two UK (Manchester and 
Belfast) and two Australian (Brisbane and Newcastle) 
centres of the HAPO study, referred to as HAPO (4).
2. Norwich: these data were routinely collected between 
2008 and February 2014 on women who had an oral 
glucose tolerance test (OGTT) on the basis of the 
presence of one or more RFs for GDM. The results 
were obtained from laboratory records with no 
identifiers. RFs in addition to those recommended 
by NICE were used (eg, women with polycystic ovary 
syndrome, previous stillbirth or recurrent glycosuria).
Table 1 Diagnostic thresholds for plasma glucose evaluated in the economic model
Threshold name Fasting (mmol/L) 1 hour (mmol/L) 2 hours (mmol/L)
No diagnosis/no treatment – – –
NICE 2015 ≥5.6 – ≥7.8
WHO 2013 ≥5.1 ≥10.0 ≥8.5
NICE, National Institute for Health and Care Excellence.
Figure 1 Model schematic. GDM, gestational diabetes mellitus; NICE, National Institute for Health and Care Excellence; OGTT, 
oral glucose tolerance test. 
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3. Atlantic Diabetes in Pregnancy (DiP): these data were 
collected between 2007 and 2013 as part of a research 
initiative in Ireland intended to improve pregnancy 
outcomes for women with diabetes before, during and 
after pregnancy.
For the HAPO (4) and Atlantic DiP datasets, the popu-
lations were stratified according to whether or not they 
had NICE RFs for GDM (body mass index above 30 kg/
m2, previous baby with birth weight ≥4.5 kg, previous 
GDM, first-degree relative with diabetes and minority 
ethnic family origin with a high prevalence of diabetes). 
This facilitated a comparison of the cost-effectiveness of 
universal screening for GDM when compared with an RF 
approach.
The NICE RF approach could not be replicated exactly 
because the patient data used in the model do not 
include information on previous offspring birth weight, 
and the HAPO (4) dataset does not provide information 
on previous GDM. Similarly, the Atlantic DiP dataset does 
not include data on previous macrosomia or previous 
GDM. Therefore, the comparison in the model was 
between universal screening and a subset of NICE RFs. 
Our Norwich dataset only included the plasma glucose 
values from a 3-point (fasting, 1 and 2 hours) OGTT, and 
therefore, it was not possible to assess cost-effectiveness 
according to the presence of RFs in this group.
Permission was obtained from the relevant Caldecott 
Guardian to use anonymised patient OGTT data from 
the Norfolk and Norwich University Hospitals National 
Health Service (NHS) Foundation Trust for the anal-
ysis. The principal investigators from the Australian 
(Professor HD McIntyre) and British (Professor DR 
McCance) centres of the HAPO study and the principal 
investigator of the Atlantic DiP (Professor F Dunne) study 
gave permission for anonymised patient data from their 
studies to be used in the analysis.
Clinical outcomes
The agreed outcomes for the economic model were 
selected prior to model development by the NICE Guide-
line Development Group. They were:
1. Shoulder dystocia (SD): this was used to estimate 
serious perinatal complications (SPCs), a broader 
composite outcome (death, SD and birth trauma) used 
as a primary outcome in clinical trials. The estimation 
of SPC from SD has been described elsewhere.6
2. Caesarean section (CS)
3. Neonatal intensive care unit (NICU) admission
4. Jaundice requiring phototherapy
5. Pre-eclampsia (PE)
6. Induction of labour
Outcomes were prioritised for inclusion in the model if 
they had a direct impact on health-related quality of life 
and/or cost. Birth weight was not included because there 
were few long-term outcome data for modelling any risk 
benefit of a reduction in birth weight for future diabetes 
and other health outcomes in the offspring.
In addition, outcomes were only included if the rela-
tionship with plasma glucose levels had been established 
in the HAPO study and also that they had been assessed 
in intervention studies used to derive treatment effect size 
estimates. Possible double counting of certain outcomes 
was taken into account (eg, preterm birth and NICU 
admission). The final list of outcomes included in the 
model was therefore a pragmatic one.
baseline risk
Logistic regression analyses of patient data from HAPO 
(4) were used to predict a baseline risk for all six 
outcomes for each woman, based on their characteristics 
including their OGTT results. In the HAPO study, OGTT 
was blinded to the carers, unless there was overt diabetes, 
thus allowing direct comparison of OGTT with perinatal 
outcomes without intermediate treatment effects for 
those meeting the new diagnostic criteria for GDM.
For each of the six outcomes, two logistic analyses to 
predict risk were assessed:
1. Prediction based on OGTT plasma glucose results 
and including the same covariates as used for model 
2 in the original analysis of the HAPO data1—this 
could not be applied to the Norwich and Atlantic DiP 
datasets as information on all HAPO covariates was 
not available.
2. Prediction based only on OGTT plasma glucose 
results.
Backward elimination of plasma glucose variables with 
non-significant coefficients was undertaken to arrive at a 
‘final’ logistic regression analysis to predict baseline risk 
for each outcome for the base case analysis, although a 
sensitivity analysis is also presented where the model was 
run with plasma glucose variables with non-significant 
coefficients retained. The logistic regression analyses 
used to predict the baseline risk for each outcome are 
shown in the online supplementary report, tables x2–x7. 
The Cholesky decomposition of the variance covariance 
matrices from the regression analyses used in the base 
case probabilistic sensitivity analysis (PSA) is given in 
online supplementary report, tables x8–x13.
Clinical effectiveness
For each evaluated diagnostic threshold in table 1, the 
model determined whether a woman would be identified 
as having GDM based on her OGTT. If the woman was 
not identified as having GDM, then outcome probabil-
ities were based on the predicted baseline risk, but for 
women identified as having GDM, the predicted base-
line risk was modified to take account of the effects of 
treatment. Treatment effectiveness for most outcomes 
was estimated from a random-effects meta-analysis of 
two studies, the Australian Carbohydrate Intolerance 
Study (ACHOIS) and the Landon et al trial.11 12 Other 
published studies of treatment for GDM were adjudged to 
lack adequate randomisation.13 For the NICU outcome, 
only the Landon et al trial data were used as it was consid-
ered to more closely represent UK practice as all neonatal 
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nursery admissions were used. Similarly, the incidence of 
PE seemed high in ACHOIS in both arms, and again only 
Landon et al trial data were used. The treatment effects 
for each of the model’s clinical outcomes are shown in 
table 2 along with parameters for probabilistic sampling. 
The model assumes that the relative treatment effect will 
be the same irrespective of the absolute baseline risk. For 
deterministic analyses, the point estimate of relative risk 
was used, but in order to account for uncertainty in these 
point estimates, these relative risks were sampled from a 
log-normal distribution in the simulations undertaken for 
PSA.
Costs
Costing was undertaken from the perspective of NHS, was 
calculated for each woman in the dataset being analysed 
and was made up of three components:
 ► the costs of the diagnostic test—not applied in the no 
test/no treat strategy;
 ► the costs of treatment—applied to every woman diag-
nosed with GDM at a particular threshold;
 ► the costs associated with the various outcomes—with 
the cost for each woman being the expected (or av-
erage) cost of the outcome based on her estimated 
risk.
The costs calculated for each woman were then summed 
across the entire patient dataset to give a total cost for a 
particular diagnostic threshold.
Costs are presented in pounds sterling and were taken 
from published UK sources where possible (cost year 
2015). They have not been discounted as they are all 
assumed to occur within 12 months of diagnosis. Model 
unit costs are reported in the online supplementary 
table x14. The costing methodology and assumptions are 
described in greater detail elsewhere.6
Other event probabilities
Probabilities in decision analysis were used to calculate 
the expected costs and benefits of the various compara-
tors. Many of these probabilities stemmed from relative 
treatment effects, but a few additional event probabilities 
were included in the model in order to estimate certain 
costs. These probabilities are shown in table 3, and their 
source is described elsewhere.6
Quality-adjusted life years
Following previous studies,6 14 a quality-adjusted life year 
(QALY) decrement of 2.2 was assigned to SPCs, defined 
as per the ACHOIS study as a composite outcome of SD, 
death and birth trauma.11 More detail on the derivation 
of this QALY loss is provided in the online supplementary 
report (including online supplementary table x15). The 
cost-effectiveness of a healthcare intervention is deter-
mined by the opportunity cost of the health foregone 
on the basis that, with a fixed health budget, any newly 
funded intervention would displace the least cost-ef-
fective treatment currently provided. In the UK, NICE 
typically uses a threshold of £20 000–30 000 per QALY as a 
benchmark15 for the opportunity cost of health foregone, 
and this paper assesses cost-effectiveness accordingly.
sensitivity analysis
PSA, using Monte Carlo simulation (with 2000 iterations 
for each analysis), was undertaken in order to assess the 
impact of sampling uncertainty on model inputs. Parame-
ters and distributions for the PSA are given in table 2 and 
online supplementary report, table x14. For the logistic 
regression coefficients used to predict baseline risk, the 
Cholesky decomposition method16 was used to sample 
from a multivariate normal distribution in order to reflect 
correlations between the coefficients.
results
Table 4 shows the percentage of women diagnosed with 
GDM in the three populations using both of the evalu-
ated diagnostic thresholds. In addition, for the HAPO 
Table 2 Relative treatment effects for model outcomes
Outcome Relative risk (RR) SE (log RR) Source
Shoulder dystocia 0.41 0.316 ACHOIS (2005), Landon (2009)
Caesarean section 0.88 0.095 ACHOIS (2005), Landon (2009)
NICU 0.77 0.194 Landon (2009)
Jaundice requiring phototherapy 0.83 0.136 ACHOIS (2005), Landon (2009)
Pre-eclampsia 0.46 0.345 Landon (2009)
Induction of labour 1.16 0.126 ACHOIS (2005), Landon (2009)
ACHOIS, Australian Carbohydrate Intolerance Study; NICU, neonatal intensive care unit.
Table 3 Model event probability not derived from patient 
level regression
Event Probability (%)
Not requiring hypoglycaemic therapy 
when treated for GDM
36
Risk of hypoglycaemia if taking 
hypoglycaemic therapy
20
Risk of hypoglycaemia being severe 
(requiring hospitalisation)
5
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(4) and Atlantic DiP datasets, this is additionally broken 
down in the subgroups with and without NICE RFs.
Detailed deterministic and probabilistic results for 
HAPO (4) with RFs are shown in tables 5–7 and figure 2.
Table 5 indicates that there was a relatively small differ-
ence in clinical outcomes contrasting NICE and WHO 
diagnostic criteria, despite there being a 45% increase 
in women diagnosed with GDM. Using the WHO 2013 
criteria, instead of the NICE 2015 criteria, an additional 
142 women would have been diagnosed with GDM and 
treated in order to prevent one case of SD.
In the deterministic analysis, the NICE 2015 diagnostic 
criteria would be considered cost-effective at a cost-effec-
tiveness threshold of £30 000 per QALY (table 6).
PSA reached a similar conclusion, with the NICE 2015 
diagnostic threshold having the highest probability of 
being the most cost-effective treatment and the highest 
net monetary benefit (NMB) using a cost-effectiveness 
threshold of £30 000 per QALY (table 7 and figure 2). The 
analysis also suggested that no diagnosis/no treatment 
might be considered the most likely to be cost-effective 
when using a lower cost-effectiveness threshold of £20 000 
per QALY. The probability of no diagnosis/no treatment 
being cost-effective falls sharply in the cost-effectiveness 
threshold range of £20 000–30 000 per QALY. As shown 
in the cost-effectiveness acceptability curve in figure 2, 
the WHO 2013 diagnostic threshold becomes more 
cost-effective as the cost-effectiveness threshold increases. 
Nevertheless, this would have to exceed £30 000 per 
QALY before becoming cost-effective, indicating that 
the further reduction in adverse outcomes is achieved 
at an unacceptably high opportunity cost. The online 
supplementary report plots the incremental cost and 
QALY outcomes of 2000 simulations from the probabi-
listic analysis on the cost-effectiveness plane (see figure 
x1). While most points fall in the south-western quadrant, 
suggesting that WHO 2013 diagnostic criteria are likely 
to lead to additional QALYs when compared with NICE 
2015 criteria, all points show that NICE 2015 criteria were 
associated with markedly lower costs.
Summaries of results for all of the model populations 
and more detailed results are provided in the online 
supplementary report (tables x16–x27 and figures x2–
x5).
Tables x28 and x29 in the online supplementary report 
show that, in both the HAPO (4) and Atlantic DiP popu-
lations with NICE RFs, the NICE diagnostic threshold 
is the most cost-effective strategy at a cost-effectiveness 
threshold of £30 000 per QALY. The NICE 2015 diag-
nostic threshold has incremental cost-effectiveness ratios 
(ICERs) of less than £30 000 per QALY, and in the PSA, it 
has the highest NMB and the highest probability of being 
the most cost-effective. For HAPO (4), the results are 
similar if baseline risks are estimated using logistic regres-
sion based on all covariates or a logistic regression just 
using plasma glucose levels.
The results also suggested that universal screening 
would not be cost-effective as, when compared with RF 
screening (as recommended in NICE guidelines), the 
additional women included in such an approach would be 
those without RFs, and the model demonstrates that the 
ICERs for diagnosis and treatment are all well in excess 
of £30 000 per QALY, markedly so when using WHO 2013 
diagnostic thresholds. These conclusions were supported 
by an analysis of the Norwich dataset (see online supple-
mentary report).
It was not possible to stratify the Norwich dataset 
according to RFs, and therefore, the ICERs presented 
relate to a comparison between no screening/treat-
ment and universal screening and treatment. However, 
the results were consistent with those for HAPO (4) and 
Atlantic DiP. First, they showed that universal screening 
was not cost-effective even when compared with an alter-
native of no screening/no treatment. Second, the ICERs 
for the whole population were a weighted average of 
the populations with and without RFs. The ICER for the 
Table 4 Percentage of women identified with GDM by threshold and population
Threshold 
name
Norwich
(n=12 754) (%)
HAPO all
(n=6163) (%)
HAPO
RF
(n=3549) (%)
HAPO
No RF
(n=2614) (%)
DiP
All
(n=5290) (%)
DiP
RF
(n=1988) (%)
DiP
No RF
(n=3302) (%)
NICE 2015 7.0 13.6 17.7 8.0 13.1 25.0 5.9
WHO 2013 13.9 18.9 25.7 9.7 21.2 37.7 11.2
DiP, Diabetes in Pregnancy; GDM, gestational diabetes mellitus; HAPO, Hyperglycaemia and Adverse Pregnancy Outcomes; NICE, National 
Institute for Health and Care Excellence; RF, risk factor.
Table 5 Clinical outcomes for HAPO (4) population with NICE risk factors (n=3549)
Diagnostic threshold Diagnosed SD SPC CS NICU Jaund PE IOL
No treatment 0 49 67 759 345 219 146 974
NICE 2015 629 41 56 739 326 210 123 1004
WHO 2013 912 39 54 731 321 207 117 1016
CS, caesarean section; IOL, induction of labour; Jaund, jaundice requiring phototherapy; NICE, National Institute for Health and Care 
Excellence; NICU, neonatal intensive care unit; PE, pre-eclampsia; SD, shoulder dystocia.
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population without RFs would be higher than the ICER 
for the entire population, which was only marginally 
below the £30 000 per QALY threshold.
deterministic sensitivity analysis
As part of a sensitivity analysis, the deterministic models 
were rerun using the logistic regression models without 
backward elimination of glucose variables with non-signif-
icant coefficients, and these analyses are discussed in the 
online supplementary report with the results summarised 
in online supplementary tables x30.
dIsCussIOn
In the NICE guideline analysis, 14 alternative diagnostic 
thresholds were compared and there was no single optimal 
diagnostic threshold that clearly emerged.6 This is not 
surprising given the small differences in patient outcomes 
between them. In that analysis, the previous WHO 1999 
criteria emerged as a relatively cost-effective strategy. 
However, the Guideline Development Group rejected a 
fasting threshold of 7.0 mmol/L as there was a wide clin-
ical consensus that this was too high, as 6.1–7.0 mmol/L is 
diagnostic of impaired fasting glycaemia in the non-preg-
nant population. Intervention studies had used a lower 
fasting threshold than 7.0 mmol/L as a basis for inclusion 
and therefore made a case for intervention at lower levels. 
Based on detailed cost-effectiveness analysis of all the 
options, the Guideline Development Group ultimately 
decided on recommending a fasting plasma glucose of 
5.6 mmol/L and a 2-hour plasma glucose of 7.8 mmol/L. 
In this paper, we have restricted our analysis of cost-effec-
tiveness to the WHO 2013 and NICE 2015 criteria (with a 
no screening/treatment baseline also included) as these 
two recommendations have the most clinical currency at 
present.
All of the analyses presented in this paper suggest 
that, in a population with NICE RFs, the NICE 2015 
diagnostic criteria for GDM could be considered cost-ef-
fective relative to no screening/no treatment and to 
WHO 2013 diagnostic thresholds when using a cost-ef-
fectiveness threshold of £30 000 per QALY. The analyses 
also show that no screening/no treatment is cost-effec-
tive in populations without NICE RFs, suggesting that 
universal screening does not represent value for money, 
at least in a UK setting. The slight differences in the 
costs and QALYs in the current analysis compared with 
the original NICE guideline are due to a combination 
of using updated cost data and a modification of the 
statistical analysis using the Cholesky decomposition 
(see the Methods section).
One of the limitations of our analysis was that the 2-hour 
threshold was restricted to the historical WHO 1999 2-hour 
definition of 7.8 mmol/L or the new WHO 2013 criteria 
of 8.5 mmol/L. It is conceivable that a 2-hour threshold 
lying between these values might outperform both. Our 
greater focus though was on the optimal fasting level as 
this is where the greatest controversy lies with respect to 
potentially missed treatment opportunities.
As noted by the proponents of WHO 2013 diag-
nostic criteria for GDM, using a lower fasting plasma 
glucose threshold would by definition detect more cases. 
Furthermore, because we assumed in the model that the 
relative treatment effect would be the same in addition-
ally diagnosed cases, it follows that such a threshold could 
potentially yield the lowest number of adverse outcomes 
and the greatest QALY gain. However, our analysis 
Table 6 Deterministic analysis for the HAPO (four centres) population with NICE risk factors (n=3549)
Diagnostic threshold Cost* QALY* Incremental cost Incremental QALY ICER
No treatment £0 0.00 n/a n/a n/a
NICE 2015 £546 349 26.78 £546 349 26.78 £23 073
WHO 2013 £778 993 34.35 £254 376 7.57 £37 669
*Costs and QALYs are measured relative to a baseline of no treatment.
HAPO, Hyperglycaemia and Adverse Pregnancy Outcomes; ICER, incremental cost-effectiveness ratio; NICE, National Institute for Health and 
Care Excellence; QALY, quality-adjusted life year.
Table 7 Probabilistic sensitivity analysis for HAPO (4) in a population with NICE risk factors
Diagnostic threshold
NMB*
CE threshold £30 000 per 
QALY
Probability cost-effective
CE threshold £20 000 per QALY 
(%)
Probability cost-effective
CE threshold WTP=£30 000 per 
QALY (%)
No treatment £0 54.1 21.0
NICE 2015 £239 902 43.3 51.5
WHO 2013 £186 675 2.7 27.6
*NMB is measured relative to a baseline of no treatment
CE, cost-effectiveness; HAPO, Hyperglycaemia and Adverse Pregnancy Outcomes; NICE, National Institute for Health and Care Excellence; 
NMB, net monetary benefit; QALY, quality-adjusted life year; WTP, willingness to pay.
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suggests that the relatively small additional gains are not 
justified by the substantially higher costs that such lower 
thresholds would require.
A key driver of our results were the logistic regression 
models that were used to predict baseline risk. For the 
outcomes included in this study, these regression models 
suggested that the 2-hour plasma glucose was a much 
more important predictor of adverse outcomes than the 
fasting plasma glucose, something we were unaware of 
when selecting the model’s clinical outcomes. For the 
regression models fitted to predict baseline risk in the 
HAPO (4) dataset with covariates and backward elimina-
tion of the OGTT plasma glucose variables (model 1 base 
case analysis regressions in online supplementary tables 
x2–x7), the Hosmer-Lemeshow Goodness of Fit Test 
did not indicate evidence of poor fit (p>0.05). However, 
there was evidence of poor fit (p<0.05) for the regression 
models of CS and NICU admission where the prediction 
was based only on OGTT plasma glucose results (model 
2 base case analysis regressions in online supplementary 
tables x2–x7). Nevertheless, as indicated in online supple-
mentary tables x28 and x29, the choice of prediction 
model did not have a large bearing on cost-effectiveness.
We consider that our analysis, which builds on previous 
modelling,6 14 is, together with another recently published 
UK analysis,10 one of the most comprehensive assess-
ments of the cost-effectiveness of diagnostic thresholds 
for GDM yet undertaken and will hopefully contribute to 
the WHO’s expectation ‘that a substantial body of new 
data will emerge in the near future, providing currently 
scarce health and economic evaluation of the recom-
mended criteria applied to various populations and with 
different approaches (universal screening, screening only 
women at high risk, diagnostic testing only)’.4
A number of commentators17 18 have recently advo-
cated universal screening for GDM. The essence of the 
argument is based on the number of cases of GDM that 
would be missed with selective screening and the subse-
quent reduced opportunity to prevent a serious perinatal 
outcome. Of course it is true that universal screening will 
detect more cases, although the absolute numbers will 
depend on the thresholds used to define GDM. Table 5 
shows that many more women would need to be diag-
nosed in order to prevent a single adverse outcome.
However, in the context of finite healthcare resources, it 
must be accepted that it may be cost-effective to miss some 
cases. Epidemiological measures such as number needed 
to treat (or number needed to screen in this case) implic-
itly recognise that a goal of healthcare systems cannot 
be to maximise health gain without any consideration 
of cost. Identifying missed cases carries an opportunity 
cost, and it may be that those resources would achieve 
greater benefit if employed elsewhere in the healthcare 
system. If a population is divided into those with RFs and 
those without RFs, then the prevalence of GDM must be 
lower in the group without RFs (and the number needed 
Figure 2 Cost-effectiveness acceptability curve indicating the probability of a diagnostic criteria or a no diagnosis/no 
treatment strategy being cost-effective at different cost-effectiveness thresholds for the HAPO (4) centres population with risk 
factors. NICE, National Institute for Health and Care Excellence.
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to screen higher) with concomitantly lower cost-effec-
tiveness. However, the comparative cost-effectiveness of 
screening in those with and without RFs is affected by the 
respective prevalence in the two groups and differences 
in severity. In those diagnosed with GDM and who had 
RFs, there were, as anticipated, greater levels of hyper-
glycaemia than in those without RFs. As shown in table 
x31able x31 in the online supplementary report, ‘true 
positives’ or identified cases (RF present and GDM) had 
higher plasma glucose values than ‘false negatives’ or 
missed cases (RFs absent and GDM) when defining GDM 
positives according to WHO 2013 diagnostic thresholds.
We would therefore expect the women with RFs and 
GDM to be at greater risk of adverse outcomes than the 
women with GDM without RFs as a result of their higher 
plasma glucose levels. So the ‘cases’ missed with selec-
tive screening would have, on average, fewer adverse 
outcomes than in cases in a population with RFs. Thus, 
the ICER would be greater in the population without RFs 
because prevalence is lower and cases have fewer adverse 
outcomes. Our analysis, by splitting the HAPO (4) and 
Atlantic DiP datasets into those with and without RFs, 
was able to evaluate the cost-effectiveness of moving from 
RF screening to universal screening. While diagnosis in 
populations with RFs was shown to be cost-effective at a 
threshold of £30 000 per QALY, it was never cost-effec-
tive to diagnose and treat in those without RFs. Table 4 
indicates the large differences that exist in prevalence 
between the populations with and without RFs. Our anal-
ysis suggests that the cost-effectiveness threshold would 
have to substantially exceed currently accepted UK norms 
for universal screening to be considered cost-effective. 
Although the NICE RF approach could not be replicated 
exactly, we felt that the approximation used was accept-
able, as the only women who would be omitted from the 
model RF population were multiparous and would have 
had a large baby previously and/or a history of GDM. 
This approximation would overestimate slightly the bene-
fits of universal screening, as the baseline risk in a group 
designated as being without NICE RFs present would be 
over-stated.
A previous study8 from Spain using WHO 2013 diag-
nostic criteria suggested cost-effectiveness compared 
with a two-step protocol using the Carpenter-Coustan 
thresholds. However, this was largely based on estimates 
of reduction of CS rates of 50%, which we find implau-
sible based on changes in diagnostic criteria alone, 
noting that ACHOIS and Landon et al found only a 
4% and 21% reduction in CS, respectively, as a result of 
treating gestational diabetes. The Spanish study did not 
consider other alternative thresholds and was a retrospec-
tive before-and-after analysis, which has been criticised 
by the Cochrane Collaboration as it does not control for 
possible changes in important variables, such as clinical 
management, over time.19
A recently published UK Health Technology Assessment 
(HTA)10 suggested that the identification of gestational 
diabetes for treatment is not cost-effective, in which 
case finding a cost-effective threshold becomes some-
what redundant. Although the HTA followed a similar 
approach to our analysis, there were some differences 
that could explain the different conclusions. In our anal-
ysis, jaundice was included as an outcome and the relative 
treatment effect would have tended to lower the incre-
mental costs of intervention as a result of reduced rates 
of phototherapy. This was not included as an outcome in 
HTA. Instrumental delivery was included as an outcome in 
HTA but not in our analysis. While instrumental delivery 
rates could in theory be increased by treatment, as there 
will be more vaginal births, this could be counteracted 
by those mothers not treated delivering larger babies 
vaginally requiring assistance; this would be in accord 
with the HTA meta-analysis that failed to demonstrate a 
treatment effect on instrumental delivery rates. In addi-
tion, HTA reported smaller treatment effects for NICU 
admission and PE. Unlike our analysis, HTA did not 
assume 100% uptake of OGTT and that would have led 
to a smaller estimate of treatment benefit. We made the 
simplifying assumption of 100% OGTT uptake because 
the view of the Guideline Development Group was that 
uptake would be much higher in a group screened on the 
basis of RFs. HTA also assumed higher uptake of OGTT 
with RF screening compared with universal screening but 
less than 100%. As we do not find universal screening to 
be cost-effective, then relaxing the assumption of 100% 
OGTT uptake would only reinforce that result. We inves-
tigated the impact of relaxing the assumption of 100% 
uptake in groups screened on the basis of RFs but found 
that it made a negligible difference to the results. For 
example, in a deterministic analysis of the HAPO (4) 
with NICE RFs, the ICER of NICE 2015 relative to no 
screening/no treatment only increased from £20 400 per 
QALY with 100% OGTT uptake to £20 585 per QALY with 
90% test uptake.
However, the differences between this analysis and HTA 
should not be overstated. Neither analysis suggests that 
universal screening for GDM is cost-effective, and like the 
HTA, our results would not support the identification and 
treatment of gestational diabetes if a cost-effectiveness 
threshold of £20 000 per QALY was used. However, it was 
the view of the Guideline Development Group that the 
clinical benefit of identifying and treating women with 
GDM is widely practiced and that a no identification/no 
treat policy would not be acceptable to patients or health-
care providers. As such, the group felt that the higher cost 
threshold of £30 000 was justified.
Our model has a number of limitations particularly with 
respect to the valuation of health outcomes. We did not 
include large for gestational age as an outcome because 
it was felt that SD was the relevant immediate complica-
tion of interest and that possible long-term metabolic 
consequences for the offspring were hard to quantify and 
therefore difficult to incorporate within the model. As 
previously noted, the QALY loss from an SPC used in this 
analysis is likely to be overstated because of the relatively 
large weight given to death based on the intervention 
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studies.14 HAPO failed to show an association between 
perinatal mortality and plasma glucose levels, which may 
mean that perinatal mortality reduction is less amenable 
to reduction by treatment than other SPCs. In this respect, 
the cost-effectiveness of diagnosing and treating GDM 
may be overstated. On the other hand, the model does 
not take account of any potential long-term effects on the 
offspring (eg, adiposity and the likelihood of subsequent 
pathology) as these effects are difficult to quantify but may 
underestimate the QALY gain from diagnosis and treat-
ment. A US study20 considered the potential long-term 
benefits to the mother whereby a diagnosis of GDM averts 
or delays onset of type 2 diabetes mellitus, but this was not 
incorporated into our model as we did not consider that 
the relationship was sufficiently well established at this 
time. However, to the extent that such a relationship does 
exist, our model would also underestimate the QALY gain 
from a diagnosis of GDM. A recent review has, however, 
questioned the association between maternal glycaemia 
and subsequent cardio-metabolic outcomes in offspring 
in humans,21 and a recent follow-up study failed to find 
evidence of a reduction in childhood obesity or metabolic 
dysfunction at 5 years in the offspring of women treated 
for mild gestational diabetes in the study of Landon et 
al.12 22
Despite these caveats, we feel that our analysis 
represents a robust analysis of the cost-effectiveness of 
the NICE versus the WHO 2013 diagnostic thresholds for 
GDM based on our current understanding of the impact 
of intervention in women with GDM in the UK popula-
tion. We acknowledge completely that this analysis cannot 
be the final word on the subject and that further health 
economic evaluation is required to either corroborate our 
findings or to challenge them. Nevertheless, our analysis 
represents a constructive and evidence-based contribu-
tion to establishing cost-effective diagnostic thresholds 
for GDM and will hopefully lead to more research to 
clarify this important but vexed area of clinical diagnosis.
COnClusIOns
The results presented in this analysis, based on a UK 
setting, do not suggest that the diagnostic thresholds for 
GDM adopted by the WHO are cost-effective. On the 
other hand, they do provide some support for the cost-ef-
fectiveness of the diagnostic criteria adopted by NICE 
when compared with either no screening/treatment and 
to WHO 2013 diagnostic criteria. Furthermore, according 
to this analysis, universal screening would seem to offer 
poor value for money and does not appear cost-effective 
compared with the current NICE guidance of targeting 
high risk women .
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